Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Compensatory dose calculations to mitigate the deleterious effect of unscheduled treatment interruptions remain important. They may be increasingly required during and after epidemics, as with the present Covid-19 virus. The information presented to those involved in the actual dose estimations is often limited, thereby increasing the likelihood of confusion, further time delays and possibly incorrect decisions. This article sets out what aspects need to be considered by the Clinical Oncologist (or Radiation Oncologist), and the reasons why, in order to provide greater clarity. The key issues are: (a) the biological nature of the tumour (and hence its repopulation potential), (b) patient age and pre-existing medical risk factors that influence radiation tolerance, the use of chemotherapy, surgery etc, (c) the acceptable dose limits of the relevant normal tissues at risk and (d) consideration of the possibility of further field size adjustments, a change in treatment plan or acceptance of a greater role for alternative forms of radiation treatment (e.g. brachytherapy, electron boosts, etc.) or reliance on radical surgery. Only then can a compensatory schedule be more safely estimated.

Original publication

DOI

10.1259/bjro.20200041

Type

Journal

BJR Open

Publication Date

2020

Volume

2